Health Care & Life Sciences » Biotechnology | Taxus Cardium Pharmaceuticals Group Inc.

Taxus Cardium Pharmaceuticals Group Inc. | Income Statement

Fiscal year is January-December. All values USD Thousands.
2012
2013
2014
2015
2016
Sales/Revenue
785.30
109.20
-
-
-
Cost of Goods Sold (COGS) incl. D&A
437.10
269.10
41.20
9.90
20.00
Gross Income
348.30
159.90
41.20
9.90
20.00
SG&A Expense
8,738.10
6,746.40
3,535.10
3,105.10
2,821.00
EBIT
8,389.80
6,906.30
3,576.30
3,115.00
2,841.00
Unusual Expense
64.20
-
1,834.70
500.00
-
Non Operating Income/Expense
-
0.80
94.60
-
-
Interest Expense
4.20
-
-
82.60
172.80
Pretax Income
8,323.30
6,906.80
5,505.50
3,697.60
3,013.80
Consolidated Net Income
8,323.30
6,906.80
5,505.50
3,697.60
3,013.80
Net Income
8,323.30
6,906.80
5,505.50
3,697.60
2,918.20
Net Income After Extraordinaries
8,323.30
4,899.30
5,505.50
3,697.60
2,918.20
Net Income Available to Common
8,323.30
9,320.20
5,505.50
4,325.30
3,701.10
EPS (Basic)
1.40
1.33
0.50
0.34
0.28
Basic Shares Outstanding
5,922.70
6,995.70
11,121.90
12,859.90
13,333.10
EPS (Diluted)
1.41
1.33
0.50
0.34
0.28
Diluted Shares Outstanding
5,922.70
6,995.70
11,121.90
12,859.90
13,333.10
EBITDA
8,109.30
6,637.20
3,535.10
3,105.10
2,821.00
Non-Operating Interest Income
6.60
0.20
-
-
-
Minority Interest Expense
-
-
-
-
95.60
Preferred Dividends
-
405.90
-
627.70
782.90

About Taxus Cardium Pharmaceuticals Group

View Profile
Address
11750 Sorrento Valley Road
San Diego California 92121
United States
Employees -
Website http://www.cardiumthx.com
Updated 07/08/2019
Taxus Cardium Pharmaceuticals Group, Inc. is regenerative therapeutics company . The company focuses on the late-stage clinical and development of regenerative medicine therapeutics. Its product candidates include Generx, an interventional cardiology, angiogenic gene therapy product candidate designed for the treatment of cardiac microvascular insufficiency due to increasing coronary artery disease; and Excellagen, an acellular biological skin substitute designed as a wound care product for the treatment of chronic non-healing diabetic foot, venous and pressure ulcers.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.